GRI - GRI Bio, Inc.
1.47
-0.130 -8.844%
Share volume: 136,183
Last Updated: 05-09-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.09%
PREVIOUS CLOSE
CHG
CHG%
$1.60
-0.13
-0.08%
Fundamental analysis
46%
Profitability
35%
Dept financing
34%
Liquidity
50%
Performance
60%
Performance
5 Days
-17.88%
1 Month
-2.65%
3 Months
-82.07%
6 Months
-82.07%
1 Year
-82.07%
2 Year
-82.07%
Key data
Stock price
$1.47
DAY RANGE
$1.45 - $1.65
52 WEEK RANGE
$1.10 - $11.12
52 WEEK CHANGE
-$82.07
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-24-2025
NEXT EARNINGS DATE
05-09-2025
Company detail
CEO: W. Marc Hertz
Region: US
Website: gribio.com
Employees: 1
IPO year: 2008
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: gribio.com
Employees: 1
IPO year: 2008
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.
Recent news
